Dr. John Cush RheumNow
2 years 6 months ago
How do you manage enthesitis?
Enthesitis can be a challenge for clinicians to identify, evaluate, and manage in patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).
https://t.co/9SHM5aZAly https://t.co/KWYnhymsVr
Dr. John Cush RheumNow
2 years 6 months ago
IV zoledronic acid (ZA) of PBO was given to 222 pts with symptomatic knee osteoarthritis (without severe joint space narrowing) and after 7 yrs of F/U, ZA had no effect on Knee OA progression w/ similar TKR Rates (39% vs 30%) https://t.co/P09EvRmApO https://t.co/s5fL1unM45
Continuing with the theme of clinical pearls, the PsA and SpA speakers also provided a wealth of information. Here are my five key takeaways and clinical pearls.
Dr. John Cush RheumNow
2 years 6 months ago
Retrospective analysis of the Australian Scleroderma Cohort Study, finds 43% of SSc pts have evidence of myopathy. From 1786 participants, 155 had prox. weakness, 24% CK elevation & 4% prox weak+CK^ (latter in more severe SSc) https://t.co/cB4Ul6VMB2 https://t.co/uAIMaotPdv
The ARIAA trial tested the utility of IV abatacept in individuals ACPA+ arthralgia patients with subclinical inflammation and showed abatacept to decrease MRI inflammation, clinical symptoms, and risk of future rheumatoid arthritis (RA) development.
Dr. John Cush RheumNow
2 years 6 months ago
Long-Term, open-label study enrolled EGPA (MIRRA study) required prednisolone ≥5 mg/d, pts cont mepolizumab 300 mg Sc q 4 wks +SOC. 100 pts - 71% completed, 3% d/C due to AEs. Exposure~38 mos; 38% serious AEs (30/100PYs) (worsening of asthma, EGPA https://t.co/8qrbFigc9T https://t.co/7QP8qGfsSm
Dr. John Cush RheumNow
2 years 6 months ago
Top 5 Clinical Pearls in RA Management
#RNL2024 provided a wealth of clinical insights, particularly in the realm of rheumatoid arthritis (RA) management. Here are the top five clinical pearls from the event's opening session, "Success in RA."
https://t.co/QrtnbeLxRZ https://t.co/5K2YRzvzcp
Dr. John Cush RheumNow
2 years 6 months ago
Serious infx (SIE) is prevalent in SLE given RTX. TOtal of 174 SLE pts on RTX -- SIE rate was high at 51/100 PYs (Pneumonia 30/100 PYs; PJP in 6.1/100 PYs).12 deaths. SIE risk factors were CKD (HR 2.9), Pred ≥15 /day (HR 3.5). HCQ decreased SIE (HR 0.35) https://t.co/8GcSQx8nxh https://t.co/oZvMgTxKVI
Dr. John Cush RheumNow
2 years 6 months ago
APIPPRA Trial: Abatacept in at-risk rheumatoid arthritis patients
Abatacept has been studied in seropositive clinically suspect arthralgia patients (at risk for rheumatoid arthritis) and shows the potential to delay or prevent the disease.
https://t.co/w944yaXNOd https://t.co/UvTVRTK1er
Is temporal artery ultrasound equivalent or superior to the reference standard of temporal artery biopsy when diagnosing giant cell arteritis (GCA)?
Dr. John Cush RheumNow
2 years 6 months ago
TLL-018 (oral dual JAK & TYK2 inhibitor) studied in chronic urticaria unresponsive to H2 blockers and was well tolerated and showed high efficacy in moderate-to-severe patients https://t.co/FDa60c5H24 https://t.co/BhHfPaLbfE
Dr. John Cush RheumNow
2 years 6 months ago
5 yr prospective observational study of 246 pts w/ nonradiographic Axial Spa shows that 16% of nr-axSpA progressed to r-axSpA w/in 5 yrs. SI progression more likely w/ Male sex (HR 3.16), imaging sacroiliitis (HR 6.6), & good NSAID response (HR 4.6) https://t.co/vAoE1CVkUf https://t.co/32r0TXxCDq
Dr. John Cush RheumNow
2 years 6 months ago
Oral IL-23 Inhibitor Effective in Psoriasis
The NEJM has published the results of the FRONTIER 1 trial demonstrating the efficacy of JNJ-77242113, an oral interleukin-23 (IL-23) receptor antagonist peptide, in patients with psoriasis (PSO).
https://t.co/NRK8LnM5zp https://t.co/FnWEze976O
Once again RheumNow Live 2024 really delivered with high impact learning packed into short sessions. As someone with an interest in vasculitis it was fantastic to see four of my favorite speakers in the Vasculitis Mavens and STEP talks. They gave us what we really want from these talks – personal opinions and approaches that go beyond the guidelines.
Dr. John Cush RheumNow
2 years 6 months ago
Retrospective cohort analysis of 330 psoriasis pts - 83 (25%) developed #PsA after mean of 36 (3.5–114) mos. PsA Predictive factors include being female (OR=3.33), nails involved (OR=5.4), severe PSO (OR=27.4), po systemic Rx prior to PsA (4.1) https://t.co/w2OO0t3PtR https://t.co/0oh5fDqVhJ
